Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.
Not all reports are available for public preview. For more information, please contact us.
Focus of the Report: The focus of this Health Technology Assessment is to evaluate the effectiveness and safety of dry needling (DN) compared with standard therapies to treat chronic pain of the neck or upper trapezius in adults.
Technology Description: DN (also called intramuscular st…
Veozah is an NK3 receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.
Delandistrogene moxeparvovec is a single-infusion gene therapy for the treatment of Duchenne muscular dystrophy.
The Globe Pulsed Field Mapping and Ablation System is an investigational pulsed-field ablation system for treatment of atrial fibrillation.
Exagamglogene autotemcel is an investigational gene therapy delivered by autologous hematopoietic stem cell transplantation for the treatment of transfusion-dependent beta thalassemia.
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of male-to-female (MtF) gender-affirming surgery (GAS) for adolescents with gender dysphoria (GD).
Focus of Report: The focus of this Health Technology Assessment is to evaluate the effectiveness and safety of transoral incisionless fundoplication (TIF) 2.0 when performed concomitantly with laparoscopic hiatal hernia repair (concomitant transoral incisionless fundoplication [cTIF]) for the treatment of chronic gastroesophageal reflux disea…
Focus of the Report: The focus of this Health Technology Assessment (HTA) is to evaluate the effectiveness and safety of transoral incisionless fundoplication (TIF) 2.0 using EsophyX (EndoGastric Solutions Inc.) to treat chronic gastroesophageal reflux disease (GERD) in adults.
Technology Des…
Arexvy (respiratory syncytial virus vaccine, adjuvanted; GSK plc) is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 years of age and older.
Focus of the Report: This Health Technology Assessment focuses on the use of pulsed radiofrequency for the treatment of chronic cervical spinal pain indications.
Technology Description: Pulsed radiofrequency (PRF) application is a minimally invasive pain management procedure performed …